Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 16, 2026

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
06:43

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Published on: April 3, 2026

Neoadjuvant imatinib for borderline resectable GIST.

M Zach Koontz1, Brendan M Visser, Pamela L Kunz

  • 1Stanford University School of Medicine, California, USA.

Journal of the National Comprehensive Cancer Network : JNCCN
|December 11, 2012
PubMed
Summary

A patient with a large gastrointestinal stromal tumor (GIST) received neoadjuvant imatinib therapy, which facilitated surgical resection. This highlights the potential of tyrosine kinase inhibitors in managing borderline resectable GISTs.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dihydropyrimidine dehydrogenase testing: From Pharmacogenomics to Equitable Practice.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Associations between Patterns of Neuroendocrine Liver Metastatic Burden and Outcomes after Liver-Directed Therapy, Systemic Chemotherapy, and Peptide Receptor Radionuclide Therapy.

Neuroendocrinology·2026
Same author

Clinical Trial Patient Matching: A Real-Time, Common Data Model and Artificial Intelligence-Driven System for Semiautomated Patient Prescreening in Cancer Clinical Trials.

JCO clinical cancer informatics·2026
Same author

Transdifferentiation in <i>TSC2</i>-Mutant Metastatic Pancreatic Neuroendocrine Tumor.

JCO precision oncology·2026
Same author

First Autopsy-confirmed Complete Remission of Metastatic Neuroendocrine Neoplasm of Tailgut Cyst After a Single Cycle of Alpha-Peptide Receptor Radionuclide Therapy With [ 225 Ac]Ac-DOTA-LM3.

Clinical nuclear medicine·2025
Same author

Consensus guideline for the management of peritoneal metastases from neuroendocrine neoplasms.

Cancer·2025

Area of Science:

  • Gastroenterology and Oncology
  • Surgical Oncology

Background:

  • Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract.
  • Management of large or borderline resectable GISTs can be challenging, often requiring multimodal treatment approaches.

Observation:

  • A 36-year-old woman presented with symptoms of gastrointestinal bleeding and syncope.
  • Diagnostic workup revealed a large duodenal mass, identified as a spindle cell neoplasm consistent with GIST.
  • The tumor's proximity to the superior mesenteric vein and common bile duct indicated borderline resectability.

Findings:

  • Neoadjuvant imatinib therapy, a tyrosine kinase inhibitor, was administered to reduce tumor size and facilitate surgical resection.
  • Pathologic and radiographic data informed the understanding of neoadjuvant therapy's mechanism and kinetics in GIST treatment.

Related Experiment Videos

Last Updated: May 16, 2026

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
06:43

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Published on: April 3, 2026

  • Successful surgical intervention was achieved following neoadjuvant imatinib treatment.

    • Implications:

    • Neoadjuvant imatinib therapy is an emerging strategy for borderline resectable GISTs, potentially improving surgical outcomes.
    • Further research is needed to establish optimal dosing, duration, and imaging protocols for neoadjuvant tyrosine kinase inhibitor therapy in GIST.
    • This case underscores the clinical utility of neoadjuvant imatinib in complex GIST cases, enabling curative-intent surgery.